CURRENT
TREATMENTS
& TRIALS
CURRENT TREATMENTS & TRIALS
for advanced HNSCC are suboptimal with few targeted therapies available.1
CURRENT TREATMENTS for advanced HNSCC are suboptimal with few targeted therapies available.1
Today, there is a clear unmet need in the care of advanced head and neck squamous cell carcinoma (HNSCC). Even with the availability of immuno-oncology therapies, second-line treatments for HNSCC provide little clinical benefit for many patients.2-4
*Based on patients with R/M HNSCC who progressed on prior therapies in 2 studies. Outcomes may differ with other treatment regimens such as combination, single-agent, or targeted therapies.
In heavily pretreated R/M HNSCC patients with a high mutant HRAS variable allele frequency, treatment with current standard of care therapies (including cetuximab, nivolumab, and pembrolizumab) has led to a historical response rate of around 15% and an overall survival rate of approximately 5.1 to 8.4 months.1
TRIALS that target HRAS mutations and overexpression and PIK3CA mutations and amplification are currently enrolling patients with R/M HNSCC
Patient enrollment is open for the following clinical trials: